{"id":1967,"date":"2026-05-08T09:13:00","date_gmt":"2026-05-08T09:13:00","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/08\/b-cell-repopulation\/"},"modified":"2026-05-08T09:13:00","modified_gmt":"2026-05-08T09:13:00","slug":"b-cell-repopulation","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2026\/05\/08\/b-cell-repopulation\/","title":{"rendered":"B cell repopulation"},"content":{"rendered":"<div class=\"twitter-share\"><a href=\"https:\/\/twitter.com\/intent\/tweet?url=https%3A%2F%2Fmultiple-sclerosis-research.org%2F2026%2F05%2Fb-cell-repopulation%2F&#038;via=the_MSBlog\" class=\"twitter-share-button\" data-size=\"large\">Tweet<\/a><\/div>\n<p>This looks at repopulation after depletion and I have to say if finds what others find in definining characteristics associated which repopulation e.g. younger age etc<\/p>\n<p>Marefi A, Grasso EA, Garber L, Narula S, Waldman A, Bar-Or A, Banwell B, Hopkins SE. Factors Influencing Early and Late B-Cell Repopulation After Rituximab Therapy in Paediatric Central Nervous System Inflammatory Disorders. Pediatr Neurol. 2026 Apr 2;180:1-8. doi: 10.1016\/j.pediatrneurol.2026.03.026.<\/p>\n<p><strong>Objectives:&nbsp;<\/strong>To identify factors associated with early and late B-cell repopulation in pediatric patients with neuroimmune disorders treated with rituximab (RTX), and to provide practical guidance on treatment protocols.<\/p>\n<p><strong>Methods:&nbsp;<\/strong>This single-center retrospective study included paediatric patients with central nervous system neuroinflammatory disorders treated with RTX from January 2014 to December 2023, and who had at least one CD19+ B-cell test. B-cell depletion was defined as an absolute CD19+ cell count of \u226410 cells\/\u03bcL after treatment. Early repopulation was defined as &gt;10 cells\/\u03bcL at 150 days; late repopulation was considered as \u226410 cells\/\u03bcL after 210 days. Predictors of early and late B-cell repopulation were evaluated using univariate and multivariate generalized linear mixed models. Relapses during B-cell repopulation and adverse events were recorded across all participants.<\/p>\n<p><strong>Results:&nbsp;<\/strong>The study included 152 patients. <em>Early B-cell repopulation was <\/em>noted in 32 patients and was <em>associated with younger age at first infusion<\/em> (odds ratio [OR] = 0.2, 95% confidence interval [CI]: 0.1-0.4). <em>Late repopulation<\/em> in 52 patients <em>was associated to older age at first infusion<\/em> (OR = 1.09, 95% CI: 1.02-1.16) and higher number of infusions (OR = 1.17, 95% CI: 1.08-1.2). Patients with multiple sclerosis did not experience relapses during repopulation. Patients switched to a single RTX dose remained adequately depleted. Adverse events were reported in 26% of the cohort, with hypogammaglobulinemia being the most common (23\/152, 15%).<\/p>\n<p><strong>Conclusions:&nbsp;<\/strong>Age and the number of infusions influence the timing of B-cell repopulation. Tailoring RTX regimens and ongoing monitoring, considering age, diagnosis, and treatment duration, can optimize RTX benefits while minimizing risks.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiple-sclerosis-research.org\/2026\/05\/b-cell-repopulation\/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=b-cell-repopulation\" rel=\"nofollow noopener\" target=\"_blank\">multiple-sclerosis-research.org<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Tweet This looks at repopulation after depletion and I have to say if finds what others find in definining characteristics associated which repopulation e.g. younger age etc Marefi A, Grasso EA, Garber L, Narula S, Waldman A, Bar-Or A, Banwell B, Hopkins SE. Factors Influencing Early and Late B-Cell Repopulation After Rituximab Therapy in Paediatric&#8230;<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1967","post","type-post","status-publish","format-standard","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1967","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1967"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1967\/revisions"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1967"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1967"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1967"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}